Localized scleroderma

Dermatologic Therapy

Volumn 25, Issue 2, 2012, Pages 135-147

  Kreuter, Alexander ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Atrophoderma idiopathica of Pierini and Pasini; Eosinophilic fasciitis; Linear morphea "en coup de sabre"; Localized scleroderma; Morphea; Parry Romberg syndrome; Progressive facial hemiatrophy; Shulman syndrome

Indexed keywords

5 HYDROXYTRYPTOPHAN; ANTIMALARIAL AGENT; BALICATIB; BLEOMYCIN; BOSENTAN; CALCIPOTRIOL; CALCITRIOL; CARBIDOPA; CORTICOSTEROID; CYCLOSPORIN; GAMMA INTERFERON; IMIQUIMOD; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PENICILLIN G; PHYTOMENADIONE; PSORALEN; TACROLIMUS;

AUTOIMMUNE DISEASE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE RELEASE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DOPPLER FLOWMETRY; DRUG MECHANISM; EOSINOPHILIC FASCIITIS; HEMIFACIAL ATROPHY; HISTOPATHOLOGY; HUMAN; INCIDENCE; LOCALIZED SCLERODERMA; LOW DRUG DOSE; MONOTHERAPY; MORPHEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PHOTOTHERAPY; RARE DISEASE; REVIEW; SCORING SYSTEM; SEROLOGY; SKIN FIBROSIS; ULTRAVIOLET A RADIATION;

DERMATOLOGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; METHOTREXATE; PHOTOTHERAPY; SCLERODERMA, LOCALIZED; SEVERITY OF ILLNESS INDEX;

EID: 84862518242     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2012.01479.x     Document Type: Review

References (99)

1. Kreuter A, Krieg T, Worm M, et al. AWMF Guideline no. 013/066. Diagnosis and therapy of circumscribed scleroderma. J Dtsch Dermatol Ges 2009: 7 (Suppl. 6): 1-14.
2. Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011: 64: 217-228.
3. Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol 2008: 59: 385-396.
4. Zulian F, Athreya BH, Laxer R, et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 2006: 45: 614-620.
5. Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 1997: 24: 73-80. (Pubitemid 27059861)
6. Murray KJ, Laxer RM. Scleroderma in children and adolescents. Rheum Dis Clin North Am 2002: 28: 603-624.
7. Silman A, Jannini S, Symmons D, Bacon P. An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol 1988: 27: 286-290.
8. Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol 2009: 145: 545-550.
9. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004: 18: 816-827.
10. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994: 37: 278-288.
11. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995: 287: 193-197.
12. Kreuter A, Hyun J, Skrygan M, et al. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol 2006: 155: 600-607. (Pubitemid 44215493)
13. Yamamoto T. Chemokines and chemokine receptors in scleroderma. Int Arch Allergy Immunol 2006: 140: 345-356. (Pubitemid 44114483)
14. Gambichler T, Skrygan M, Labanski AA, Kolios AG, Altmeyer P, Kreuter A. Significantly increased CCL5/RANTES and CCR7 mRNA levels in localized scleroderma. Regul Pept 2011: 170: 4-6.
15. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007: 117: 557-567. (Pubitemid 46348510)
16. Eisendle K, Grabner T, Zelger B. Morphoea: a manifestation of infection with Borrelia species? Br J Dermatol 2007: 157: 1189-1198. (Pubitemid 350115703)
17. Colome-Grimmer MI, Payne DA, Tyring SK, Sanchez RL. Borrelia burgdorferi DNA and Borrelia hermsii DNA are not associated with morphea or lichen sclerosus et atrophicus in the southwestern United States. Arch Dermatol 1997: 133: 1174. (Pubitemid 27408230)
18. Dillon WI, Saed GM, Fivenson DP. Borrelia burgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North America. J Am Acad Dermatol 1995: 33: 617-620.
19. Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G. Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol 2008: 59: 125-129.
20. Bleasel NR, Stapleton KM, Commens C, Ahern VA. Radiation-induced localized scleroderma in breast cancer patients. Australas J Dermatol 1999: 40: 99-102. (Pubitemid 29215261)
21. Davis DA, Cohen PR, McNeese MD, Duvic M. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol 1996: 35: 923-927. (Pubitemid 26422116)
22. Sommer A, Gambichler T, Bacharach-Buhles M, von Rothenburg T, Altmeyer P, Kreuter A. Clinical and serological characteristics of progressive facial hemiatrophy: a case series of 12 patients. J Am Acad Dermatol 2006: 54: 227-233. (Pubitemid 43144391)
23. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995: 70: 1068-1076.
24. Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol 2006: 18: 606-613. (Pubitemid 44607414)
25. Jacobson L, Palazij R, Jaworsky C. Superficial morphea. J Am Acad Dermatol 2003: 49: 323-325. (Pubitemid 36951290)
26. Jablonska S, Blaszczyk M. Is superficial morphea synonymous with atrophoderma Pasini-Pierini? J Am Acad Dermatol 2004: 50: 979-980. (Pubitemid 38685790)
27. Weibel L, Harper JI. Linear morphoea follows Blaschko's lines. Br J Dermatol 2008: 159: 175-181. (Pubitemid 351874511)
28. Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol 2007: 56: 257-263. (Pubitemid 46074261)
29. Blaszczyk M, Krolicki L, Krasu M, Glinska O, Jablonska S. Progressive facial hemiatrophy: central nervous system involvement and relationship with scleroderma en coup de sabre. J Rheumatol 2003: 30: 1997-2004. (Pubitemid 37075551)
30. Orozco-Covarrubias L, Guzman-Meza A, Ridaura-Sanz C, Carrasco Daza D, Sosa-de-Martinez C, Ruiz-Maldonado R. Scleroderma "en coup de sabre" and progressive facial hemiatrophy. Is it possible to differentiate them? J Eur Acad Dermatol Venereol 2002: 16: 361-366. (Pubitemid 34918818)
31. Chung L, Lin J, Furst DE, Fiorentino D. Systemic and localized scleroderma. Clin Dermatol 2006: 24: 374-392. (Pubitemid 44332868)
32. Krieg T, Takehara K. Skin disease: a cardinal feature of systemic sclerosis. Rheumatology (Oxford) 2009: 48 (Suppl. 3): iii14-iii18.
33. Takehara K, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford) 2005: 44: 274-279. (Pubitemid 40361280)
34. Sato S, Fujimoto M, Kikuchi K, Ihn H, Tamaki K, Takehara K. Soluble CD4 and CD8 in serum from patients with localized scleroderma. Arch Dermatol Res 1996: 288: 358-362. (Pubitemid 26232086)
35. Vierra E, Cunningham BB. Morphea and localized scleroderma in children. Semin Cutan Med Surg 1999: 18: 210-225. (Pubitemid 29384283)
36. Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma. Arthritis Rheum 2004: 50: 227-232. (Pubitemid 38084308)
37. Tomimura S, Ogawa F, Iwata Y, et al. Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma. J Dermatol Sci 2008: 52: 47-54.
38. Yimane K, Ihn H, Kubo M, Asano Y, Yazawa N, Tamaki K. Anti-U3 snRNP antibodies in localised scleroderma. Ann Rheum Dis 2001: 60: 1157-1158. (Pubitemid 33096087)
39. Ihn H, Yazawa N, Kubo M, et al. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol 2000: 27: 698-702. (Pubitemid 30151349)
40. Hasegawa M, Sato S, Nagaoka T, Fujimoto M, Takehara K. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology 2003: 207: 141-147. (Pubitemid 37034341)
41. Hulshof MM, Bouwes Bavinck JN, Bergman W, et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000: 43: 1017-1023.
42. Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol 2011: 64: 231-242.
43. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995: 22: 1281-1285.
44. Arkachaisri T, Vilaiyuk S, Li S, et al. The localized scleroderma skin severity index and Physician Global Assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol 2009: 36: 2819-2829.
45. Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA Jr. Development and initial validation of the localized scleroderma skin damage index and Physician Global Assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford) 2010: 49: 373-381.
46. Bendeck SE, Jacobe HT. Ultrasound as an outcome measure to assess disease activity in disorders of skin thickening: an example of the use of radiologic techniques to assess skin disease. Dermatol Ther 2007: 20: 86-92. (Pubitemid 46817423)
47. Morita A, Kobayashi K, Isomura I, Tsuji T, Krutmann J. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000: 43: 670-674.
48. Enomoto DN, Mekkes JR, Bossuyt PM, Hoekzema R, Bos JD. Quantification of cutaneous sclerosis with a skin elasticity meter in patients with generalized scleroderma. J Am Acad Dermatol 1996: 35: 381-387. (Pubitemid 26299226)
49. de Rie MA, Enomoto DN, de Vries HJ, Bos JD. Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method. Dermatology 2003: 207: 298-301. (Pubitemid 37329201)
50. Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Reliability of two methods to assess morphea: skin scoring and the use of a durometer. J Am Acad Dermatol 1997: 37: 793-796. (Pubitemid 27500332)
51. Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol 1998: 39: 220-225. (Pubitemid 28367333)
52. Karrer S, Abels C, Landthaler M, Szeimies RM. Topical photodynamic therapy for localized scleroderma. Acta Derm Venereol 2000: 80: 26-27. (Pubitemid 30110844)
53. Kroft EB, van de Kerkhof PC, Gerritsen MJ, de Jong EM. Period of remission after treatment with UVA-1 in sclerodermic skin diseases. J Eur Acad Dermatol Venereol 2008: 22: 839-844. (Pubitemid 351850083)
54. Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 2009: 10: 181-187.
55. Birdi N, Shore A, Rush P, Laxer RM, Silverman ED, Krafchik B. Childhood linear scleroderma: a possible role of thermography for evaluation. J Rheumatol 1992: 19: 968-973.
56. Martini G, Murray KJ, Howell KJ, et al. Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatology (Oxford) 2002: 41: 1178-1182. (Pubitemid 35203548)
57. Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol 2006: 155: 1013-1020. (Pubitemid 44564513)
58. Weibel L, Howell KJ, Visentin MT, et al. Laser Doppler flow-metry for assessing localized scleroderma in children. Arthritis Rheum 2007: 56: 3489-3495. (Pubitemid 47585445)
59. Moore TL, Vij S, Murray AK, Bhushan M, Griffiths CE, Herrick AL. Pilot study of dual-wavelength (532 and 633 nm) laser Doppler imaging and infrared thermography of morphoea. Br J Dermatol 2009: 160: 864-867.
60. Zulian F, Meneghesso D, Grisan E, et al. A new computerized method for the assessment of skin lesions in localized scleroderma. Rheumatology (Oxford) 2007: 46: 856-860. (Pubitemid 47064263)
61. Kreuter A, Gambichler T, Avermaete A, et al. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol 2001: 18: 241-245. (Pubitemid 32567879)
62. Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998: 39: 211-215. (Pubitemid 28367331)
63. Mancuso G, Berdondini RM. Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol 2005: 152: 180-182.
64. Stefanaki C, Stefanaki K, Kontochristopoulos G, et al. Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study. J Dermatol 2008: 35: 712-718.
65. Dytoc M, Ting PT, Man J, Sawyer D, Fiorillo L. First case series on the use of imiquimod for morphoea. Br J Dermatol 2005: 153: 815-820. (Pubitemid 41415912)
66. Joly P, Bamberger N, Crickx B, Belaich S. Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol 1994: 130: 663-664. (Pubitemid 24150954)
67. Michet CJ Jr, Doyle JA, Ginsburg WW. Eosinophilic fasciitis: report of 15 cases. Mayo Clin Proc 1981: 56: 27-34.
68. Uziel Y, Feldman BM, Krafchik BR, Yeung RS, Laxer RM. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000: 136: 91-95. (Pubitemid 30468564)
69. Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 2005: 141: 847-852. (Pubitemid 41058065)
70. Appelhans C, Breuckmann F, Gambichler T, Brockmeyer NH, Altmeyer P, Kreuter A. Unilateral generalized morphea is a rare variant of localized scleroderma. Eur J Med Res 2006: 11: 152-156.
71. Zulian F, Martini G, Vallongo C, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2011: 63: 1998-2006.
72. Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology (Oxford) 2009: 48: 1410-1413.
73. Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. In vitro evidence for a direct anti-fibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 2007: 321: 583-589. (Pubitemid 46624497)
74. Hunzelmann N, Anders S, Fierlbeck G, et al. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol 1997: 36: 433-435. (Pubitemid 27131967)
75. Falanga V, Medsger TA Jr. penicillamine d-in the treatment of localized scleroderma. Arch Dermatol 1990: 126: 609-612. (Pubitemid 20157672)
76. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999: 42: 1194-1203. (Pubitemid 29268956)
77. Diab M, Coloe JR, Magro C, Bechtel MA. Treatment of recalcitrant generalized morphea with infliximab. Arch Dermatol 2010: 146: 601-604.
78. Roldan R, Morote G, Castro Mdel C, Miranda MD, Moreno JC, Collantes E. Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in children. J Rheumatol 2006: 33: 2538-2540. (Pubitemid 46067838)
79. Nagy E, Ladányi E. Treatment of circumscribed scleroderma in childhood. Z Hautkr 1987: 62: 547-549.
80. Moinzadeh P, Krieg T, Hunzelmann N. Imatinib treatment of generalized localized scleroderma (morphea). J Am Acad Dermatol 2010: 63: 102-104.
81. Cribier B, Faradji T, Le Coz C, Oberling F, Grosshans E. Extracorporeal photochemotherapy in systemic sclerosis and severe morphea. Dermatology 1995: 191: 25-31.
82. Peter RU, Ruzicka T, Eckert F. Low-dose cyclosporine A in the treatment of disabling morphea. Arch Dermatol 1991: 127: 1420-1421.
83. Möhrenschlager M, Jung C, Ring J, Abeck D. Effect of penicillin G on corium thickness in linear morphea of childhood: an analysis using ultrasound technique. Pediatr Dermatol 1999: 16: 314-316. (Pubitemid 29383170)
84. Kreuter A, Gambichler T. UV-A1 phototherapy for sclerotic skin diseases: implications for optimizing patient selection and management. Arch Dermatol 2008: 144: 912-916. (Pubitemid 352039744)
85. Stein B, Rahmsdorf HJ, Steffen A, Litfin M, Herrlich P. UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein. Mol Cell Biol 1989: 9: 5169-5181. (Pubitemid 19275988)
86. Scharffetter K, Wlaschek M, Hogg A, et al. UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 1991: 283: 506-511.
87. Kerscher M, Volkenandt M, Meurer M, Lehmann P, Plewig G, Rocken M. Treatment of localised scleroderma with PUVA bath photochemotherapy. Lancet 1994: 343: 1233. (Pubitemid 24147585)
88. Breuckmann F, Gambichler T, Altmeyer P, Kreuter A. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol 2004: 4: 11.
89. Kerscher M, Meurer M, Sander C, et al. PUVA bath photochemotherapy for localized scleroderma: evaluation of 17 consecutive patients. Arch Dermatol 1996: 132: 1280-1282. (Pubitemid 26386612)
90. Grundmann-Kollmann M, Ochsendorf F, Zollner TM, et al. PUVA-cream photochemotherapy for the treatment of localized scleroderma. J Am Acad Dermatol 2000: 43: 675-678.
91. El-Mofty M, Zaher H, Bosseila M, Yousef R, Saad B. Low-dose broad-band UVA in morphea using a new method for evaluation. Photodermatol Photoimmunol Photomed 2000: 16: 43-49. 92. El-Mofty M, Mostafa W, Esmat S, et al. Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study. Photodermatol Photoimmunol Photomed 2004: 20: 93-100. (Pubitemid 38455739)
92. El-Mofty M, Mostafa W, El-Darouty M, et al. Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis. Photodermatol Photoimmunol Photomed 2004: 20: 148-156. (Pubitemid 38744933)
93. Kerscher M, Dirschka T, Volkenandt M. Treatment of localised scleroderma by UVA1 phototherapy. Lancet 1995: 346: 1166.
94. Stege H, Berneburg M, Humke S, et al. High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 1997: 36: 938-944. (Pubitemid 27265906)
95. Camacho NR, Sanchez JE, Martin RF, Gonzalez JR, Sanchez JL. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J Am Acad Dermatol 2001: 45: 697-699. (Pubitemid 33032565)
96. Sator PG, Radakovic S, Schulmeister K, Honigsmann H, Tanew A. Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment. J Am Acad Dermatol 2009: 60: 786-791.
97. Andres C, Kollmar A, Mempel M, Hein R, Ring J, Eberlein B. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study. Br J Dermatol 2010: 162: 445-447.
98. Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J AmAcad Dermatol 2011: 65: 925-941.
99. Kreuter A, Hyun J, Stucker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006: 54: 440-447. (Pubitemid 43243447)